Abstract
Background: Uterine cervical cancer is the fourth most common female cancer in the world. In Japan, we have an apparently low rate of joining cervical cancer screening programs compared with Western countries. Furthermore, the incidence and mortality rate of cervical cancer among the younger generation has been increasing. Object: The aim of this study was to assess the effectiveness of cervical cancer screening with human papillomavirus (HPV) testing and cytology in Japan. Methods: Collaborating with Saga City government, we initiated a cervical cancer screening system consisting of HPV testing and baseline cervical cytology from April 2011 as a social experiment. A total of 17,284 participants have been screened with this new combination system. Results: After HPV testing with cytology-based cervical cancer screening, the number of screenings done in women aged under 40 years has significantly increased. In addition, the number of women diagnosed with cervical intraepithelial neoplasia grade 3 has increased (25 of 14,025 vs. 146 of 23,049 under 50 years: p < 0.001). Conclusion: These data suggested that the introduction of HPV testing with cytology-based cervical cancer screening as an adjunct to conventional cytology resulted in better efficiency and more accurate screening among the Japanese population.
References
1.
Ferlay
J
, Soerjomataram
I
, Dikshit
R
, Eser
S
, Mathers
C
, Rebelo
M
, et al Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
. Int J Cancer
. 2015
Mar
;136
(5
):E359
–86
.
[PubMed]
0020-71362.
Kiviat
N
. Natural history of cervical neoplasia: overview and update
. Am J Obstet Gynecol
. 1996
Oct
;175
(4 Pt 2
):1099
–104
.
[PubMed]
0002-93783.
Lees
BF
, Erickson
BK
, Huh
WK
. Cervical cancer screening: evidence behind the guidelines
. Am J Obstet Gynecol
. 2016
Apr
;214
(4
):438
–43
.
[PubMed]
0002-93784.
Ministry of Health
. Labour and Welfare.(1958-2013).Vital Statistics Japan[Data file]. Available from: http://ganjoho.jp/pro/statistics/en/cancer_mortality(1958-2013)E.xls. Accessed December 10, 2017.5.
Mayrand
MH
, Duarte-Franco
E
, Rodrigues
I
, Walter
SD
, Hanley
J
, Ferenczy
A
, et al; Canadian Cervical Cancer Screening Trial Study Group
. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer
. N Engl J Med
. 2007
Oct
;357
(16
):1579
–88
.
[PubMed]
0028-47936.
Gustafsson
L
, Pontén
J
, Zack
M
, Adami
HO
, Adami
HO
. International incidence rates of invasive cervical cancer after introduction of cytological screening
. Cancer Causes Control
. 1997
Sep
;8
(5
):755
–63
.
[PubMed]
0957-52437.
Muñoz
N
, Bosch
FX
, de Sanjosé
S
, Herrero
R
, Castellsagué
X
, Shah
KV
, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
. Epidemiologic classification of human papillomavirus types associated with cervical cancer
. N Engl J Med
. 2003
Feb
;348
(6
):518
–27
.
[PubMed]
0028-47938.
Wallin
KL
, Wiklund
F
, Angström
T
, Bergman
F
, Stendahl
U
, Wadell
G
, et al Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
. N Engl J Med
. 1999
Nov
;341
(22
):1633
–8
.
[PubMed]
0028-47939.
Arbyn
M
, Sasieni
P
, Meijer
CJ
, Clavel
C
, Koliopoulos
G
, Dillner
J
. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006
; 24 Suppl 3: S3/78-89.10.
Cuzick
J
, Clavel
C
, Petry
KU
, Meijer
CJ
, Hoyer
H
, Ratnam
S
, et al Overview of the European and North American studies on HPV testing in primary cervical cancer screening
. Int J Cancer
. 2006
Sep
;119
(5
):1095
–101
.
[PubMed]
0020-713611.
Schlecht
NF
, Platt
RW
, Duarte-Franco
E
, Costa
MC
, Sobrinho
JP
, Prado
JC
, et al Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia
. J Natl Cancer Inst
. 2003
Sep
;95
(17
):1336
–43
.
[PubMed]
0027-887412.
Goodman
A
. HPV testing as a screen for cervical cancer
. BMJ
. 2015
Jun
;350
jun30 1
:h2372
.
[PubMed]
0959-813813.
Minakami
H
, Maeda
T
, Fujii
T
, Hamada
H
, Iitsuka
Y
, Itakura
A
, et al Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition
. J Obstet Gynaecol Res
. 2014
Jun
;40
(6
):1469
–99
.
[PubMed]
1341-807614.
Tanaka
Y
, Ueda
Y
, Kishida
H
, Hosogai
N
, Morimoto
A
, Egawa-Takata
T
, et al Trends in the cervical cancer screening rates in a city in Japan between the years of 2004 and 2013
. Int J Clin Oncol
. 2015
Dec
;20
(6
):1156
–60
.
[PubMed]
1341-962515.
Stoler
MH
, Wright
TC
Jr, Sharma
A
, Zhang
G
, Apple
R
, Wright
TL
, et al; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group
. The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study
. Am J Clin Pathol
. 2012
Feb
;137
(2
):295
–303
.
[PubMed]
0002-917316.
Phillips
S
, Cornall
AM
, Machalek
DA
, et al Comparison of the Roche Cobas(R) 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2016
;35:1305-7.17.
Wright
TC
Jr, Stoler
MH
, Behrens
CM
, Apple
R
, Derion
T
, Wright
TLl
. The ATHENA human papillomavirus study: design, methods, and baseline results.
Am J Obstet Gynecol. 2012
; 206:46.e1-.e11. 18.
Konno
R
, Shin
HR
, Kim
YT
, Song
YS
, Sasagawa
T
, Inoue
M
, et al Human papillomavirus infection and cervical cancer prevention in Japan and Korea
. Vaccine
. 2008
Aug
;26
Suppl 12
:M30
–42
.
[PubMed]
0264-410X19.
Virtanen
A
, Anttila
A
, Luostarinen
T
, Malila
N
, Nieminen
P
. Improving cervical cancer screening attendance in Finland
. Int J Cancer
. 2015
Mar
;136
(6
):E677
–84
.
[PubMed]
0020-713620.
Ueda
Y
, Sobue
T
, Morimoto
A
, Egawa-Takata
T
, Hashizume
C
, Kishida
H
, et al Evaluation of a free-coupon program for cervical cancer screening among the young: a nationally funded program conducted by a local government in Japan
. J Epidemiol
. 2015
;25
(1
):50
–6
.
[PubMed]
0917-504021.
Ushijima
K
. Current status of gynecologic cancer in Japan
. J Gynecol Oncol
. 2009
Jun
;20
(2
):67
–71
.
[PubMed]
2005-038022.
Naucler
P
, Ryd
W
, Törnberg
S
, Strand
A
, Wadell
G
, Elfgren
K
, et al Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening
. J Natl Cancer Inst
. 2009
Jan
;101
(2
):88
–99
.
[PubMed]
0027-887423.
Yagi
A
, Ueda
Y
, Kimura
T
. A behavioral economics approach to the failed HPV vaccination program in Japan
. Vaccine
. 2017
Dec
;35
(50
):6931
–3
.
[PubMed]
0264-410X24.
Sasaki
Y
, Iwanari
O
, Arakawa
I
, Moriya
T
, Mikami
Y
, Iihara
K
, et al Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan
. Int J Gynecol Cancer
. 2017
Mar
;27
(3
):523
–9
.
[PubMed]
1048-891X25.
Inoue
M
, Okamura
M
, Hashimoto
S
, Tango
M
, Ukita
T
. Adoption of HPV testing as an adjunct to conventional cytology in cervical cancer screening in Japan
. Int J Gynaecol Obstet
. 2010
Nov
;111
(2
):110
–4
.
[PubMed]
0020-729226.
Fujiwara
K
, Monk
B
, Devouassoux-Shisheboran
M
. Adenocarcinoma of the uterine cervix: why is it different?
Curr Oncol Rep
. 2014
Dec
;16
(12
):416
.
[PubMed]
1523-379027.
Talia
KL
, Stewart
CJ
, Howitt
BE
, Nucci
MR
, McCluggage
WG
. HPV-negative Gastric Type Adenocarcinoma In Situ of the Cervix: A Spectrum of Rare Lesions Exhibiting Gastric and Intestinal Differentiation
. Am J Surg Pathol
. 2017
Aug
;41
(8
):1023
–33
.
[PubMed]
0147-5185© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
